Leerink Partnrs Has Bearish Outlook for AxoGen Q4 Earnings

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Stock analysts at Leerink Partnrs lowered their Q4 2025 earnings per share estimates for shares of AxoGen in a research note issued to investors on Monday, July 14th. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.02. The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group reduced their price target on shares of AxoGen from $26.00 to $24.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $24.50.

AxoGen Price Performance

Shares of AxoGen stock traded down $0.35 during trading on Wednesday, hitting $11.28. The stock had a trading volume of 676,057 shares, compared to its average volume of 517,535. The firm has a market cap of $513.69 million, a price-to-earnings ratio of -75.19 and a beta of 1.04. The company has a current ratio of 4.28, a quick ratio of 2.65 and a debt-to-equity ratio of 0.63. AxoGen has a 12 month low of $7.34 and a 12 month high of $21.00. The business's 50-day moving average is $10.92 and its 200 day moving average is $15.12.

Insiders Place Their Bets

In other AxoGen news, Director Joseph A. Tyndall sold 20,062 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $11.20, for a total transaction of $224,694.40. Following the sale, the director directly owned 15,345 shares in the company, valued at $171,864. This represents a 56.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.78% of the stock is owned by insiders.

Institutional Trading of AxoGen

Several hedge funds and other institutional investors have recently made changes to their positions in AXGN. US Bancorp DE acquired a new position in AxoGen during the 4th quarter valued at about $30,000. State of Wyoming bought a new position in shares of AxoGen in the fourth quarter valued at approximately $31,000. Fifth Third Bancorp bought a new position in AxoGen during the first quarter worth $92,000. Harvest Fund Management Co. Ltd bought a new stake in AxoGen in the 4th quarter valued at $93,000. Finally, GAMMA Investing LLC boosted its stake in shares of AxoGen by 3,884.6% in the 1st quarter. GAMMA Investing LLC now owns 5,698 shares of the medical equipment provider's stock valued at $105,000 after purchasing an additional 5,555 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company's stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.